GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (FRA:G51) » Definitions » Change In Other Working Capital

Genscript Biotech (FRA:G51) Change In Other Working Capital : €39.5 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Genscript Biotech Change In Other Working Capital?

Genscript Biotech's Change In Other Working Capital for the quarter that ended in Dec. 2024 was €-17.6 Mil. It means Genscript Biotech's Other Working Capital declined by €17.6 Mil from Jun. 2024 to Dec. 2024 .

Genscript Biotech's Change In Other Working Capital for the fiscal year that ended in Dec. 2024 was €41.1 Mil. It means Genscript Biotech's Other Working Capital increased by €41.1 Mil from Dec. 2023 to Dec. 2024 .

Genscript Biotech Change In Other Working Capital Historical Data

The historical data trend for Genscript Biotech's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Change In Other Working Capital Chart

Genscript Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.22 149.19 201.34 41.94 41.12

Genscript Biotech Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 154.36 -30.64 72.38 57.12 -17.60

Genscript Biotech Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €39.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genscript Biotech Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (FRA:G51) » Definitions » Change In Other Working Capital
Comparable Companies
HKSE:01877 HKSE:09995 HKSE:02696 HKSE:09969 HKSE:09606 HKSE:06855 HKSE:01952 HKSE:06826 HKSE:02171 HKSE:02162 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
GNNSF:USA 01548:Hong Kong
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
Website
https://www.genscript.com
Genscript Biotech Corp is a China-based provider of life science research services and products. The firm is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. The company's business segments include Life-science services and products, Biologics development services, Industrial synthetic biology products, and the Operation unit. The company generates the majority of its revenue from the life-science services and products unit, which provides comprehensive research services and products, which are widely used and are fundamental to life-science research and application. Geographically, the company generates the majority of its revenue from the United States of America, followed by Mainland China.

Genscript Biotech Headlines

No Headlines